During the corresponding time, Arcutis Biotherapeutics Inc recorded a revenue increase by 59.33 % year on year, sequentially revenue grew by 23.21 %. While revenue at the Arcutis Biotherapeutics Inc 's corporate clients
Arcutis Biotherapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs, including Medicaid and Medicare. Its clients include health care practitioners such as physicians (doctors, dentists, optometrists, podiatrists, chiropractors), non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, certified nurse-midwives), and teaching hospitals, which receive payments or transfers of value from prescription drug manufacturers. The company operates in states including California, Connecticut, Nevada, and Massachusetts, where pharmaceutical companies are required to implement compliance programs, marketing codes, and register pharmaceutical sales representatives. Its market segments encompass federal and state health care programs and various health care providers subject to reporting and compliance regulations.
Arcutis Biotherapeutics, Inc. has made groundbreaking strides in dermatology with their novel medication, ZORYVE (Roflumilast) Cream 0.15%. This cream has shown promising results from the recently pooled subgroup analysis of Phase 3 INTEGUMENT-1 and INTEGUMENT-2 clinical trials, setting a new benchmark for the treatment of atopic dermatitis (AD) across diverse skin types. These findings weren t just limited to clinical improvements for patients, but they also translated into remarkable financial growth for the company. In a span of one year, Arcutis Biotherapeutics witnessed an unprecedented 5156.41% increase in revenue, with a sequential quarterly growth of 634.28%. Clinical Efficacy Across Diverse Skin Typ...
Arcutis Announces Groundbreaking Results for ZORYVE in the Treatment of Mild to Moderate Atopic Dermatitis WESTLAKE VILLAGE, Calif. Sept. 19, 2024 Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a rising star in the realm of biopharmaceutical innovation, has turned heads yet again with the publication of positive results from two pivotal Phase 3 trials, INTEGUMENT-1 and INTEGUMENT-2, evaluating the safety and efficacy of ZORYVE™ (roflumilast) cream, 0.15%. Featured in the prestigious Journal of American Medical Association Dermatology (JAMA Dermatology), this research underscores the potential of ZORYVE as a once-daily, steroid-free treatment for mild to moderate atopic dermatitis (AD).Atopic dermatiti...
Arcutis Biotherapeutics: A Game-Changer in Dermatology with Dual FDA ApprovalsArcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a company that prides itself on pioneering advancements in immuno-dermatology, is making significant strides in transforming the treatment landscape for chronic skin conditions. With recent U.S. Food and Drug Administration (FDA) approvals for two different formulations of their flagship product ZORYVE (roflumilast), the company s innovative approach is positioning it as a formidable player in the dermatology space. Breaking Ground with ZORYVE Cream for Atopic Dermatitis On December 15, 2023, Arcutis launched ZORYVE (roflumilast) cream 0.15%, designed specifically for the treatment of ...
In recent years, the medical community has witnessed significant advancements in the treatment of dermatological conditions, particularly atopic dermatitis (AD) and seborrheic dermatitis (SD). Two groundbreaking studies conducted by Arcutis Biotherapeutics, Inc. have unveiled the potential of roflumilast cream as a highly effective therapeutic option for children and adults suffering from these chronic skin disorders. This article aims to explore the exciting findings presented in these studies and their implications for patients worldwide.Study 1 - INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5:Arcutis recently reported the results of their INTEGUMENT-PE...
Arcutis Biotherapeutics Inc, a leading innovator in dermatology therapeutics, has recently announced the publication of positive results from the pivotal Phase 3 STRATUM trial evaluating the efficacy of ZORYVE (roflumilast) foam, 0.3% for the treatment of seborrheic dermatitis. Published in the Journal of the American Academy of Dermatology (JAAD), these findings highlight the potential of ZORYVE foam as an effective and safe treatment option for patients suffering from this chronic skin condition.Background on Seborrheic Dermatitis:Seborrheic dermatitis is a common, chronic inflammatory skin condition that primarily affects areas of the body rich in sebaceous glands, such as the scalp, face, and trunk. The ...
Arcutis Biotherapeutics, a pioneering immuno-dermatology company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for their new drug application (NDA) of ZORYVE (roflumilast) topical foam, 0.3%. This revolutionary foam has been specifically developed to treat seborrheic dermatitis in individuals aged 9 years and older. The efficacy and groundbreaking mechanism of action of ZORYVE are expected to revolutionize the treatment landscape for this common skin condition. Groundbreaking Treatment for Seborrheic Dermatitis: Seborrheic dermatitis, a chronic inflammatory skin condition affecting millions worldwide, can cause severe itchiness, dis...
Arcutis Biotherapeutics, an early commercial-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for roflumilast cream 0.15%. This topical cream aims to provide a steroid-free treatment for atopic dermatitis (AD) in both adults and children as young as six years old. With a Prescription Drug User Fee Act (PDUFA) target action date of July 2024, Arcutis Biotherapeutics has high hopes for the approval of this innovative therapy. Progress in Atopic Dermatitis Treatment: Atopic dermatitis, a chronic inflammatory skin condition, affects millions of people worldwide. This condition often causes i...
Arcutis Biotherapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs, including Medicaid and Medicare. Its clients include health care practitioners such as physicians (doctors, dentists, optometrists, podiatrists, chiropractors), non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, certified nurse-midwives), and teaching hospitals, which receive payments or transfers of value from prescription drug manufacturers. The company operates in states including California, Connecticut, Nevada, and Massachusetts, where pharmaceutical companies are required to implement compliance programs, marketing codes, and register pharmaceutical sales representatives. Its market segments encompass federal and state health care programs and various health care providers subject to reporting and compliance regulations.
Sources:
Arcutis Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arcutis Biotherapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Arcutis Biotherapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
52.36 %